About this episode
Drug development has always been a long and arduous process, taking years of research and costing millions of dollars. When some biotech companies started to use artificial intelligence as part of that process, it was seen as a tool that had the potential to revolutionize drug discovery. Ten years on, those companies are faced with a reality check.
Globe business reporters Joe Castaldo, who covers AI, and Sean Silcoff, who reports on technology and life sciences, are on the show to talk about the promise of AI in drug development, and why the bets on technology haven’t panned out.
Questions? Comments? Ideas? Email us at [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time The Decibel publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Decibel
How much AI music is in your playlist?
The Decibel
What war in Iran means for Canadian oil
The Decibel
Why holding government to account in Ontario could get harder
The Decibel
Behind schedule and over budget: Why do we keep building LRTs?
The Decibel